In the rapidly evolving field of imaging patients with biochemical recurrence of prostate cancer [24, 25], 18F-fluciclovine is, along with choline and PSMA ligand radiopharmaceuticals, an “advanced” or “next-generation” radiotracer that has gained broad clinical usage. This evidence concerns the gene FOLH1 and prostate cancer.